Recently, mesenchymal-epithelial transition (MET) exon 14 skipping mutations (METex14) and high-level MET amplification have emerged as one of the novel, actionable oncogenic alterations in NSCLC, sensitive to MET inhibitors [4,5]. This evidence concerns the gene MET and non-small cell lung carcinoma.